PMID- 36169181
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20221016
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 48
IP  - 5
DP  - 2022 Nov
TI  - Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative 
      stress in ovarian cancer.
LID - 202 [pii]
LID - 10.3892/or.2022.8417 [doi]
AB  - Gomisin A (GA) is an effective component of Schisandra. The crude extracts of 
      Schisandra chinensis and its active ingredients have been shown to inhibit 
      multidrug resistance in tumour cells. Reactive oxygen species (ROS) have 
      different roles in cancer and may contribute to therapy resistance. The human 
      ovarian cancer (OC) cell lines SKOV3 and A2780, and a mouse model of OC, were 
      used in the present study. MTT assay, colony formation assay, flow cytometry, 
      western blot analysis, and haematoxylin and eosin (H&E) staining were performed 
      to determine the antitumor effect of GA and paclitaxel (PTX) in vitro and 
      in vivo. The ROS inhibitor N‑acetyl cysteine (NAC) was used to assess the 
      mechanism underlying the chemosensitizing effects of GA. Notably, the 
      proliferation of OC cells was inhibited by PTX, which could be enhanced by the 
      ROS inhibitor NAC or GA. Treatment with NAC + PTX or GA + PTX enhanced the cell 
      cycle arrest, but not apoptosis, induced by PTX. Moreover, the molecular 
      mechanism underlying this effect may be that GA decreases the levels of ROS in 
      ovarian cancer cells and inhibits cell cycle progression by downregulating the 
      expression of the cell cycle proteins cyclin‑dependent kinase 4 and cyclin B1. In 
      conclusion, the combination of PTX and the ROS inhibitor GA may be a novel 
      strategy in OC chemotherapy.
FAU - Wang, Taiwei
AU  - Wang T
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Huang, Xuemiao
AU  - Huang X
AD  - Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 
      Jilin 130022, P.R. China.
FAU - Zhang, Chuanqi
AU  - Zhang C
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Shangguan, Mengyuan
AU  - Shangguan M
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Chen, Junyu
AU  - Chen J
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Wu, Shan
AU  - Wu S
AD  - Department of Reproductive Endocrinology, Women's Hospital, Zhejiang University, 
      School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.
FAU - Chen, Mengmeng
AU  - Chen M
AD  - Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 
      Jilin 130022, P.R. China.
FAU - Yang, Zhaoyun
AU  - Yang Z
AD  - Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 
      Jilin 130022, P.R. China.
FAU - Zhao, Shuhua
AU  - Zhao S
AD  - Department of Gynaecology and Obstetrics, The Second Hospital, Jilin University, 
      Changchun, Jilin 130021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20220928
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Complex Mixtures)
RN  - 0 (Cyclin B1)
RN  - 0 (Cyclooctanes)
RN  - 0 (Dioxoles)
RN  - 0 (Lignans)
RN  - 0 (Reactive Oxygen Species)
RN  - 58546-54-6 (schizandrol B)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
RN  - K848JZ4886 (Cysteine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - TDQ283MPCW (Eosine Yellowish-(YS))
SB  - IM
MH  - Animals
MH  - Carcinoma, Ovarian Epithelial
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Complex Mixtures/pharmacology
MH  - Cyclin B1/metabolism
MH  - Cyclin-Dependent Kinase 4/metabolism
MH  - Cyclooctanes
MH  - Cysteine/pharmacology
MH  - Dioxoles
MH  - Eosine Yellowish-(YS)/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Lignans
MH  - Mice
MH  - *Ovarian Neoplasms/pathology
MH  - Oxidative Stress
MH  - *Paclitaxel/pharmacology/therapeutic use
MH  - Reactive Oxygen Species/metabolism
PMC - PMC9551658
OTO - NOTNLM
OT  - GA
OT  - OC
OT  - PTX
OT  - ROS
OT  - chemosensitization
COIS- The authors declare that they have no competing interests.
EDAT- 2022/09/29 06:00
MHDA- 2022/09/30 06:00
PMCR- 2022/09/27
CRDT- 2022/09/28 07:34
PHST- 2022/03/31 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/28 07:34 [entrez]
PHST- 2022/09/29 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/09/27 00:00 [pmc-release]
AID - 202 [pii]
AID - OR-48-05-08417 [pii]
AID - 10.3892/or.2022.8417 [doi]
PST - ppublish
SO  - Oncol Rep. 2022 Nov;48(5):202. doi: 10.3892/or.2022.8417. Epub 2022 Sep 28.